WuXi PharmaTech and Huawei introduce first Chinese cloud platform for individualized medicine

Under the „135“ program, WuXi and Huawei will comply with the relevant provisions of the State Food and Drug Administration (CFDA), through cooperation with third-party security life sciences cloud platform vendors, joint development for Chinese Medicine Program and precise data exchange standards and frameworks.

China Bio news release, May 25, 2016

WuXi PharmaTech and Huawei introduce first Chinese cloud platform for individualized medicine
Scroll to top